Antibody Therapeutics, Inc

Antibody Therapeutics, Inc. (株式会社抗体医学研究所) is a Japan-based drug discovery startup established in 2022 by Professor Yas Yokosaki of Hiroshima University. The company focuses on developing innovative pharmaceutical products by targeting integrins, which are cell adhesion molecules that play a critical role in tissue fibrosis. Their primary development candidate, ATI-235, is a humanized integrin-targeting antibody aimed at treating idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions. The company utilizes unique antibody technologies developed from academic research to control fibroblast activation and mitigate excessive matrix protein deposition, which drives disease progression in organs such as the lungs and liver.

This technology addresses significant unmet medical needs in patients suffering from severe and often fatal fibrotic diseases. By targeting integrins, the company aims to offer a novel therapeutic approach that could improve outcomes for millions of patients worldwide, including those with IPF, a condition currently lacking diverse treatment options. Supported by investments from entities like Mitsubishi UFJ Capital and led by a team with extensive experience in the pharmaceutical industry, Antibody Therapeutics, Inc. is currently advancing its pipeline through pre-clinical development and safety testing, working toward translating academic science into clinical applications.